급성 신손상 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Acute Kidney Injury Treatment Market - Scope of Report

TMR's report on the global acute kidney injury treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global acute kidney injury treatment market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute kidney injury treatment market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute kidney injury treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute kidney injury treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute kidney injury treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute kidney injury treatment market.

The report delves into the competitive landscape of the global acute kidney injury treatment market. Key players operating in the global acute kidney injury treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute kidney injury treatment market profiled in this report.

Key Questions Answered in global acute kidney injury treatment Market Report:

• What is the sales/revenue generated by acute kidney injury treatment across all regions during the forecast period?
• What are the opportunities in the global acute kidney injury treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Acute Kidney Injury Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute kidney injury treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute kidney injury treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute kidney injury treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Acute Kidney Injury Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product & Brand Analysis
• 5.3. Regulatory Scenario by Country/Region
• 5.4. Disease Prevalence & Incidence Rate globally with key countries
• 5.5. Mortality Rate by Type of AKI- globally with key Countries
• 5.6. Emerging Trends - By Type of AKI
  • 5.6.1. Investigational New Drug (IND) - MTX652
  • 5.6.2. Extracellular Vesicle (EV) Therapy for AKI using iNPC-derived EV
  • 5.6.3. Biomarkers for Early AKI Diagnosis
  • 5.6.4. Continuous Renal Replacement Therapy (CRRT) Advancements
  • 5.6.5. Gene Therapy in Kidney Repair
  • 5.6.6. Prevention Of NephroToxin induced Acute Kidney injury with Cilastatin
  • 5.6.7. Drug Candidate For the Treatment of AKI - UNI-494
  • 5.6.8. RMC-035-IND (Investigational New Drug)
  • 5.6.9. Artificial Intelligence in AKI
  • 5.6.10. Mesenchymal Stem Cell Therapy
• 5.7. Benchmarking of the Products Offered by the Competitors
• 5.8. Porter's Five Forces Analysis
• 5.9. PESTEL Analysis
• 5.10. Insights on Restraints/Challenges & Major Factors for Considerations & Business Models for New Entrants (Mainly OEMs)

6. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Drug Therapy

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Therapy, 2020-2035
  • 6.3.1. Vasoconstrictor Agents
  • 6.3.2. Inotropic Drugs
  • 6.3.3. Diuretics
  • 6.3.4. Intravenous (IV) Crystalloid Solution
  • 6.3.5. Immunosuppressive Drugs
  • 6.3.6. Others
• 6.4. Market Attractiveness By Drug Therapy

7. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Type, 2020-2035
  • 7.3.1. Pre-renal Acute Kidney Injury
  • 7.3.2. Intrinsic renal Acute Kidney Injury
  • 7.3.3. Post-renal Acute Kidney Injury
• 7.4. Market Attractiveness By Type

8. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Distribution Channel, 2020-2035
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Attractiveness By Distribution Channel

9. Global Acute Kidney Injury Treatment Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Region

10. North America Acute Kidney Injury Treatment Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Drug Therapy, 2020-2035
  • 10.2.1. Vasoconstrictor Agents
  • 10.2.2. Inotropic Drugs
  • 10.2.3. Diuretics
  • 10.2.4. Intravenous (IV) Crystalloid Solution
  • 10.2.5. Immunosuppressive Drugs
  • 10.2.6. Others
• 10.3. Market Value Forecast By Type, 2020-2035
  • 10.3.1. Pre-renal Acute Kidney Injury
  • 10.3.2. Intrinsic renal Acute Kidney Injury
  • 10.3.3. Post-renal Acute Kidney Injury
• 10.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast By Country, 2020-2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Drug Therapy
  • 10.6.2. By Type
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe Acute Kidney Injury Treatment Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Drug Therapy, 2020-2035
  • 11.2.1. Vasoconstrictor Agents
  • 11.2.2. Inotropic Drugs
  • 11.2.3. Diuretics
  • 11.2.4. Intravenous (IV) Crystalloid Solution
  • 11.2.5. Immunosuppressive Drugs
  • 11.2.6. Others
• 11.3. Market Value Forecast By Type, 2020-2035
  • 11.3.1. Pre-renal Acute Kidney Injury
  • 11.3.2. Intrinsic renal Acute Kidney Injury
  • 11.3.3. Post-renal Acute Kidney Injury
• 11.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Spain
  • 11.5.5. Italy
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Drug Therapy
  • 11.6.2. By Type
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country / Sub-region

12. Asia Pacific Acute Kidney Injury Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Drug Therapy, 2020-2035
  • 12.2.1. Vasoconstrictor Agents
  • 12.2.2. Inotropic Drugs
  • 12.2.3. Diuretics
  • 12.2.4. Intravenous (IV) Crystalloid Solution
  • 12.2.5. Immunosuppressive Drugs
  • 12.2.6. Others
• 12.3. Market Value Forecast By Type, 2020-2035
  • 12.3.1. Pre-renal Acute Kidney Injury
  • 12.3.2. Intrinsic renal Acute Kidney Injury
  • 12.3.3. Post-renal Acute Kidney Injury
• 12.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Drug Therapy
  • 12.6.2. By Type
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country / Sub-region

13. Latin America Acute Kidney Injury Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Therapy, 2020-2035
  • 13.2.1. Vasoconstrictor Agents
  • 13.2.2. Inotropic Drugs
  • 13.2.3. Diuretics
  • 13.2.4. Intravenous (IV) Crystalloid Solution
  • 13.2.5. Immunosuppressive Drugs
  • 13.2.6. Others
• 13.3. Market Value Forecast By Type, 2020-2035
  • 13.3.1. Pre-renal Acute Kidney Injury
  • 13.3.2. Intrinsic renal Acute Kidney Injury
  • 13.3.3. Post-renal Acute Kidney Injury
• 13.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Drug Therapy
  • 13.6.2. By Type
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country / Sub-region

14. Middle East & Africa Acute Kidney Injury Treatment Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Therapy, 2020-2035
  • 14.2.1. Vasoconstrictor Agents
  • 14.2.2. Inotropic Drugs
  • 14.2.3. Diuretics
  • 14.2.4. Intravenous (IV) Crystalloid Solution
  • 14.2.5. Immunosuppressive Drugs
  • 14.2.6. Others
• 14.3. Market Value Forecast By Type, 2020-2035
  • 14.3.1. Pre-renal Acute Kidney Injury
  • 14.3.2. Intrinsic renal Acute Kidney Injury
  • 14.3.3. Post-renal Acute Kidney Injury
• 14.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 14.4.1. Hospital Pharmacies
  • 14.4.2. Retail Pharmacies
  • 14.4.3. Online Pharmacies
• 14.5. Market Value Forecast By Country / Sub-region, 2020-2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Drug Therapy
  • 14.6.2. By Type
  • 14.6.3. By Distribution Channel
  • 14.6.4. By Country / Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. AM-Pharma
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Aptabio Therapeutics
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Arch Biopartners
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Novartis AG
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. Guard Therapeutics
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Renibus Therapeutics
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. Mission Therapeutics
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Unicycive Therapeutics Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Baxter International Inc.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. ICU Medical
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. B. Braun Melsungen AG
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Financial Overview
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments
  • 15.3.12. Fresenius Kabi
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Financial Overview
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Developments
  • 15.3.13. Amanta Healthcare
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Financial Overview
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Developments
  • 15.3.14. Pfizer, Inc.
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Financial Overview
    • 15.3.14.3. Financial Overview
    • 15.3.14.4. Business Strategies
    • 15.3.14.5. Recent Developments
  • 15.3.15. Sanofi S.A.
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Financial Overview
    • 15.3.15.3. Financial Overview
    • 15.3.15.4. Business Strategies
    • 15.3.15.5. Recent Developments